Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year ...

Shares of Rigel Pharmaceuticals RIGL have surged 59% in the past year, significantly outperforming the industry’s 2% growth.

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

Rigel Pharmaceuticals has seen its consensus analyst price target rise from $38.33 to $45.40, indicating heightened optimism about the company’s financial trajectory. This optimism coincides with a ...

CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and ...

Rigel Pharmaceuticals (NASDAQ:RIGL) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-04. Here's a quick overview of what investors should know before the release. Analysts are ...

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were $40 ...